A New Pulmonary Arterial Hypertension Drug on the Horizon
In pulmonary arterial hypertension patients, riociguat serves as a reasonable first-line alternative to PDE-5 inhibitors or in combination therapy with an endothelin antagonist or inhaled prostacyclin analogues.
Read More